You are here

  • Home
  • Archive
  • Volume 78, Issue 11
  • Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series

Article metrics

Article menu

Download PDFPDF

Correspondence
Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series
Free

 

Online download statistics by month:

Online download statistics by month: October 2018 to March 2024

AbstractFullPdf
Oct 2018416429155
Nov 2018606652262
Dec 201843943962
Jan 201935335137
Feb 201947747535
Mar 201958558549
Apr 201956756643
May 201961261155
Jun 201941741633
Jul 201934935059
Aug 201929029038
Sep 201938838731
Oct 2019455458107
Nov 201922422367
Dec 201913713755
Jan 202014614257
Feb 20201009936
Mar 202012812839
Apr 202010410431
May 2020878735
Jun 2020756927
Jul 2020807338
Aug 2020797526
Sep 2020767319
Oct 2020706819
Nov 2020928922
Dec 2020707020
Jan 2021757415
Feb 2021828122
Mar 202116315447
Apr 2021636124
May 2021797915
Jun 2021635916
Jul 2021464413
Aug 2021443721
Sep 2021605725
Oct 2021605728
Nov 2021524426
Dec 2021595215
Jan 202270689
Feb 2022434110
Mar 2022696515
Apr 202251507
May 2022858128
Jun 2022656316
Jul 202249497
Aug 2022696713
Sep 2022818426
Oct 2022887327
Nov 2022737214
Dec 2022484713
Jan 2023605714
Feb 202368679
Mar 202335359
Apr 2023171617
May 2023262617
Jun 202321205
Jul 2023312617
Aug 2023352913
Sep 2023252810
Oct 202332237
Nov 202327258
Dec 2023222013
Jan 2024363623
Feb 202414137
Mar 2024302740
Total953894532118